BioSpace News Archive

Glaucoma Research Foundation President and CEO, Thomas M. Brunner announced the 2024 Annual Gala honorees including philanthropists Judy and Charles Munnerlyn, visionary donors and glaucoma advocates The Zander Family, and artist and patient advocate Patricia Caulfield.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring.

Bioventus Inc. announced the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock and inducement restricted stock units, covering an aggregate of 11,250 shares of its common stock.

Evolus, Inc. reported the grant of non-qualified stock options to purchase an aggregate of 89,770 shares of Evolus and an aggregate of 82,730 restricted stock units of the company’s common stock to six newly hired non-executive employees of the company.

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.

The International Myeloma Foundation’s Black Swan Research Initiative® proudly showcased four oral and two poster abstracts from the iStopMM Project during the 65th American Society of Hematology Annual Meeting in San Diego, CA which took place from December 9-12, 2023.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, January 17, 2024 at 5:30 a.m. PT / 8:30 a.m. ET.

Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced successful completion of an animal safety study evaluating the Company’s proprietary ablation technology.

Every January, the global medical health and financial investment sectors turn their focus to San Francisco.